Adarza BioSystems

Founded in 2008, Adarza has developed a highly sensitive label-free diagnostic platform capable of measuring 100s more individual proteins than the best multiplex immunoassays available today. The Arrayed Imaging Reflectometry (AIR™) is a label-free platform technology that enables the simultaneous detection of hundreds of analytes in a single drop of fluid. Adarza delivers industry leading precision, accuracy, and robustness enabling highly multiplexed protein detection with high sensitivity and specificity. The company’s unique technology is flexible, data-rich, and easy to use, providing the only solution that spans the entire companion diagnostic life cycle from discovery to clinic, in both high-throughput core facilities as well as point of care (POC). Much like the first gene-chips enabled multiplexed genomics analysis, Adarza’s first-to-market high-multiplex and sensitivity antibody chips will fundamentally disrupt the field of proteomics research. Adarza is a venture capital backed company and the exclusive licensee of a broad intellectual property portfolio initially developed at University of Rochester by Dr. Benjamin Miller, Adarza’s scientific founder.
Company Growth (employees)
Type
Private
HQ
West Henrietta, US
Founded
2008
Size (employees)
22 (est)+10%
Adarza BioSystems was founded in 2008 and is headquartered in West Henrietta, US

Adarza BioSystems Office Locations

Adarza BioSystems has offices in West Henrietta and Saint Peters
West Henrietta, US (HQ)
150 Lucius Gordon Dr
Saint Peters, US
501 Pearl Dr

Adarza BioSystems Data and Metrics

Summary Metrics

Founding Date

2008

Total Funding

$31.1 m

Latest funding size

$17 m

Time since last funding

5 months

Investors

Adarza BioSystems's latest funding round in January 2017 was reported to be $17 m. In total, Adarza BioSystems has raised $31.1 m

Adarza BioSystems Company Life and Culture

You may also be interested in